APA (7th ed.) Citation

Xiao, D., Weng, J., Zhang, L., Xing, C., Wei, Y., & Chen, Y. Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Xiao, Dunming, Junling Weng, Lei Zhang, Chang Xing, Yan Wei, and Yingyao Chen. Long Term Cost-effectiveness Analysis of IDegLira in the Treatment of Type 2 Diabetes Patients Compared to GLP-1RA Added to Basal Insulin After IDegLira Entered the National Reimbursement Drug List in China. Public Library of Science (PLoS).

MLA (9th ed.) Citation

Xiao, Dunming, et al. Long Term Cost-effectiveness Analysis of IDegLira in the Treatment of Type 2 Diabetes Patients Compared to GLP-1RA Added to Basal Insulin After IDegLira Entered the National Reimbursement Drug List in China. Public Library of Science (PLoS).